Biopharmx Corp (NYSE:BPMX) was the target of a large decrease in short interest in July. As of July 31st, there was short interest totalling 4,790,336 shares, a decrease of 6.7% from the July 14th total of 5,135,164 shares. Based on an average daily volume of 697,859 shares, the short-interest ratio is presently 6.9 days. Currently, 8.3% of the shares of the company are sold short.

Separately, ValuEngine upgraded Biopharmx Corp from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 24th.

Shares of Biopharmx Corp (BPMX) opened at 0.298 on Thursday. The stock’s market cap is $22.09 million. Biopharmx Corp has a 52-week low of $0.19 and a 52-week high of $1.22. The firm has a 50-day moving average price of $0.43 and a 200 day moving average price of $0.51.

ILLEGAL ACTIVITY NOTICE: “Biopharmx Corp (NYSE:BPMX) Sees Significant Drop in Short Interest” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/10/biopharmx-corp-nysebpmx-sees-significant-drop-in-short-interest.html.

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.